Guardant Health Investor Presentation

Biopharma is a significant portion of $6B therapy selection market 1200+ targeted therapy and I-O programs 130,000+ patients ~$4 Billion Clinical Opportunity ~$2 Billion Biopharmaceutical Opportunity 50+ $250 $320 pharma partners $370 $1,180 Prospective Retrospective CDx Commercial Sources: SEER; Rebecca L. Siegel, Cancer Statistics, 2018, A Cancer Journal for Clinicians, 68:7; Piper Jaffray, Liquid Biopsy Report. Guardant Health Biopharma, Global Data, June 2017; clinicaltrials.gov; Campbell (Meyerson) and TCGA 2016 Nature Genetics. 15 GUARDANT™ Note: Market sizing based on Guardant Health internal analysis.

View entire presentation